Michael Doulberis

Dr. Michael Doulberis

Gastroenterology and Hepatology, University hospital Zurich, Zürich, Switzerland
orcid
Clinic for Gastroenterology and Hepatology, University Hospi...

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2017 in Helicobacter
Verified
Journal Article
Closed access
PDF file
Michael DoulberisMichael Doulberis
Michael Doulberis
GKGeorgios Kotronis
Georgios Kotronis
RTRobert Thomann
Robert Thomann
SPStergios A Polyzos
Stergios A Polyzos
MBMarina Boziki
Marina Boziki
JKJannis Kountouras
Jannis Kountouras

1 June 2017 in Metabolism
Verified
Journal Article
Closed access
Michael DoulberisMichael Doulberis
Michael Doulberis
GKGeorgios Kotronis
Georgios Kotronis
DGDimitra Gialamprinou
Dimitra Gialamprinou
JKJannis Kountouras
Jannis Kountouras
PKPanagiotis Katsinelos
Panagiotis Katsinelos

30 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Michael DoulberisMichael Doulberis
Michael Doulberis
SSSimone Srivastava
Simone Srivastava
SPStergios A Polyzos
Stergios A Polyzos
JKJannis Kountouras
Jannis Kountouras
APApostolis Papaefthymiou
Apostolis Papaefthymiou
David Shiva  SrivastavaDavid Shiva Srivastava
David Shiva Srivastava
Nonalcoholic fatty liver disease (NAFLD) emerges as an important global burden and Helicobacter pylori infection (Hp-I) has been suggested as a risk factor of NAFLD, although controversy exists. This retrospective study aimed to investigate a potential impact of active Hp-I on NAFLD severity in morbidly obese patients, subjected to bariatric surgery and gastric biopsy for documentation of Hp-I. Of 64 eligible participants, 15 (23.4%) were diagnosed with active Hp-I, showing higher rates of nonalcoholic steatohepatitis (NASH) than those without Hp-I (86.7% vs. 26.5%, respectively; p < 0.001). Concerning histological lesions, steatosis grade (p = 0.027), ballooning (p < 0.001), lobular inflammation (p = 0.003), and fibrosis stage (p < 0.001) were also more severe in Hp-I positive patients. Likewise, liver function tests, insulin resistance, dyslipidemia, and arterial hypertension were significantly higher in Hp-I positive patients. Hp-I was independently positively associated with NASH (beta = 3.27; p = 0.002), severe NASH (beta = 2.37; p = 0.018), and the presence of fibrosis (beta = 3.86; p = 0.001) in a binary regression model, after adjustment for potential confounders. In conclusion, active Hp-Ι was independently associated with NASH and fibrosis, findings offering potential clinical implication.

1 October 2018 in Metabolism
Verified
Journal Article
Closed access
JKJannis Kountouras
Jannis Kountouras
SPStergios A Polyzos
Stergios A Polyzos
Michael DoulberisMichael Doulberis
Michael Doulberis
CZChristos Zeglinas
Christos Zeglinas
FAFotini Artemaki
Fotini Artemaki
CMChristos S. Mantzoros
Christos S. Mantzoros

4 March 2020 in International Journal of Neuroscience
Verified
Journal Article
Closed access
Michael DoulberisMichael Doulberis
Michael Doulberis
GKGeorgios Kotronis
Georgios Kotronis
DGDimitra Gialamprinou
Dimitra Gialamprinou
SPStergios A Polyzos
Stergios A Polyzos
APApostolis Papaefthymiou
Apostolis Papaefthymiou
JKJannis Kountouras
Jannis Kountouras
Background: Alzheimer disease (AD) is a leading cause of global burden with great impact on societies. Although research is working intensively on promising therapy, the problem remains up-to-date. Among the various proposed hypotheses regarding causality and therapy, emerging evidence supports the hypothesis that gastrointestinal microbiota through the so-called “gut-brain axis” interacts with immune system and brain and shape the balance between homeostasis and disease; the involvement of gastrointestinal microbiota in the pathophysiology of AD is less defined, even though the role of “gut-brain axis” has been well verified for other neurodegenerative conditions. Methods: We performed a systematic review of PubMed/MEDLINE database from 1st January 1990 to 17th October 2018, to investigate the accessible literature regarding possible association between AD and gastrointestinal microbiota. Inclusion criteria were available full text in English language, original clinical papers implicating AD patients and any sort of gastrointestinal microbiota. Results: Through our query, an initial number of 241 papers has been identified. After removing duplicates and through an additional manual search, twenty-four papers met our inclusion criteria. The great majority of eligible publications supported a possible connection between AD and gastrointestinal microbiota. The most common investigated microorganism was Helicobacter pylori. Conclusion: Our own systematic review, showed a possible association between AD and gastrointestinal microbiota mainly including Helicobacter pylori, and thus further research is required for substantiation of causality as well as for the establishment of promising novel therapies.

26 August 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TPTheofilos Poutahidis
Theofilos Poutahidis
KCKelsey Cappelle
Kelsey Cappelle
TLTatiana Levkovich
Tatiana Levkovich
CLChung-Wei Lee
Chung-Wei Lee
Michael DoulberisMichael Doulberis
Michael Doulberis
SESusan E. Erdman
Susan E. Erdman
A role for microbes has been suspected in prostate cancer but difficult to confirm in human patients. We show here that a gastrointestinal (GI) tract bacterial infection is sufficient to enhance prostate intraepithelial neoplasia (PIN) and microinvasive carcinoma in a mouse model. We found that animals with a genetic predilection for dysregulation of wnt signaling, ApcMin/+ mutant mice, were significantly susceptible to prostate cancer in an inflammation-dependent manner following infection with Helicobacter hepaticus. Further, early neoplasia observed in infected ApcMin/+ mice was transmissible to uninfected mice by intraperitoneal injection of mesenteric lymph node (MLN) cells alone from H. hepaticus-infected mutant mice. Transmissibility of neoplasia was preventable by prior neutralization of inflammation using anti-TNF-α antibody in infected MLN donor mice. Taken together, these data confirm that systemic inflammation triggered by GI tract bacteria plays a pivotal role in tumorigenesis of the prostate gland.